- Early increase in serum TTR levels by acoramidis predicts up to 31.6% reduction in mortality risk.
- Acoramidis shows a 42% reduction in composite all-cause mortality and recurrent cardiovascular hospitalizations at Month 30, and a 50% reduction in cardiovascular hospitalization events.
- The drug, marketed as Attruby in the US and as BEYONTTRA in Europe, Japan, and the UK, demonstrates rapid therapeutic benefits.
BridgeBio Pharma Inc. (BBIO, Financial), a biopharmaceutical company focused on genetic diseases, has reported promising data from its Phase 3 ATTRibute-CM trial. The study explored the efficacy of acoramidis in treating transthyretin amyloid cardiomyopathy (ATTR-CM), revealing that each 5 mg/dL increase in serum transthyretin (TTR) levels within 28 days of initiating treatment correlates with up to a 31.6% reduction in mortality risk by Month 30.
Acoramidis treatment resulted in a swift and sustained increase in serum TTR levels, averaging 9.1 mg/dL within the first 28 days, which was maintained over a 30-month period. This increase in TTR levels was linked to a considerable 42% reduction in composite all-cause mortality and recurrent cardiovascular hospitalizations, as well as a 50% reduction in cardiovascular hospitalization frequency.
The medication, which acts as a near-complete TTR stabilizer, is now approved as Attruby™ by the U.S. FDA and as BEYONTTRA® by regulatory authorities in Europe, Japan, and the UK. Acoramidis is recognized for achieving unprecedented rapid benefits in ATTR-CM treatment, setting a new benchmark in Phase 3 studies.
These results suggest that serum TTR levels can serve as a prognostic biomarker for ATTR-CM, providing clinicians with a valuable tool for optimizing patient management and improving long-term outcomes.
